RE:RE:RE:RE:RE:RE:Cannaccord 42ndI would say he did very well projecting confidence in what they are doing, where they are, and he reiterated some of the key points a few times. He said the human results are tracking the animal results well, (as you say) the point of 1a was met in a very difficult cohort, the financing was done with a highly regarded firm in a very tough environment thus putting them on stable financial grounds for the year, the commercial side is doing well and he was very logical about what the new sales structure allows them to do, etc.. He made some key points in a short talk which is all you can do. Will it change a lot? I think it may get a few people to think they should circle back to it once there's some data on 1b. So no immediate buying interest, but perhaps building that audience shoudl there be positive news forthcoming.
One answer he gave was useful in confirming our own thinking. When asked when they'll release efficacy data he truthfully said they expect to see at least a couple prior to year end, and it could be more than that or it could be many results in a few cancers. But he never said they would likely not see anything until the new year. He was pretty adamant it would end by April next year, although he didn't state where enrollment was.
qwerty22 wrote: I thought he did a great job on explaining that 1a did what it was expected to do. I think he was very honest to say 1b is where they need to start showing efficacy. These are the basic facts now.
I thought he was bullish about the commercial area. He even managed to project some dynamism onto NASH where it probably doesn't merit it. What more do you expect from your CEO.
jfm1330 wrote: Over. This will not convince anybody to invest in Thera. Same story. Not a surprise, but that's where we are, and still the big flaw about not tsting for sortilin overexpression.
jfm1330 wrote: Nothing new on cancer. No question on ortilin testing.